AxoGen (AXGN) Stock Price
AxoGen Price
Revenue has compounded at 48.3% per year over the past 19 years to 225.21 M USD. AxoGen's net margin stands at -7.0%, up from -21.2% several years earlier. AxoGen currently offers a dividend yield of about 2.76%. Analysts set a median price target of 51.50 USD, implying 42.4% above the current price. Of 16 analysts, 15 rate the stock a buy — an overall Buy consensus.
AxoGen stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
AxoGen business model & stock analysis
Frequently asked questions about AxoGen
AxoGen Inc is a leading medical technology company focused on the development and commercialization of innovative solutions for peripheral nerve injuries. Their business model revolves around providing advanced surgical solutions to patients suffering from nerve damage. AxoGen offers a comprehensive portfolio of products and services that support nerve repair and regeneration, enabling patients to regain function and improve their quality of life. Through their cutting-edge technologies, AxoGen aims to revolutionize the field of peripheral nerve repair, bringing hope and relief to individuals with nerve injuries.
AxoGen Inc is primarily active in the healthcare industry.
The main competitors of AxoGen Inc in the market include Integra LifeSciences Holdings Corporation, Baxter International Inc., Stryker Corporation, and Medtronic plc.
AxoGen Inc. is a biotechnology company specializing in the development and commercialization of innovative surgical solutions for peripheral nerve injuries. Founded in 2002, AxoGen is headquartered in Alachua, Florida, and operates globally. The company is dedicated to advancing the science and understanding of nerve injury and regeneration through its proprietary Avance® Nerve Graft and AxoGuard® Nerve Protector products. With an experienced management team, AxoGen continues to drive innovation in nerve repair and restoration, providing hope and improved outcomes for patients suffering from nerve damage. AxoGen Inc. has established itself as a leader in the field, offering groundbreaking solutions to healthcare providers and patients worldwide.
AxoGen Inc has achieved several significant milestones throughout its history. The company has successfully developed and commercialized innovative nerve repair technology, making it a leader in the field. AxoGen has achieved FDA clearance and European CE mark approval for its products. It has also expanded its market presence by establishing distribution agreements with leading healthcare providers globally. AxoGen has consistently demonstrated strong financial performance, with increased revenues and record-breaking sales. The company's commitment to research and development has led to numerous patents and the introduction of groundbreaking surgical solutions. Overall, AxoGen Inc has made remarkable progress in transforming the field of nerve repair and continues to pave the way for future advancements.
AxoGen Inc is primarily present in the United States.
AxoGen Inc represents the values of innovation, collaboration, and patient-centricity. As a leading company in the field of nerve repair and regeneration, AxoGen is dedicated to developing and providing innovative solutions for patients with peripheral nerve injuries. Their corporate philosophy revolves around improving patient outcomes and enhancing the quality of life by delivering safe and effective treatments. By prioritizing collaboration with healthcare professionals and researchers, AxoGen ensures that their products are developed with the latest scientific advancements. With an unwavering commitment to patient well-being, AxoGen continues to make significant contributions to the field of nerve repair.
Analysts currently set an average price target of 50.17 USD for the AxoGen stock (median: 51.50 USD), implying +38.7 % versus the latest price. The consensus is based on 16 analyst ratings.
16 analysts currently rate the AxoGen stock: 15 recommend buying, 1 holding and 0 selling. For 2026, analysts expect AxoGen to generate revenue of 283.33 M USD and earnings per share of 0.45 USD.
Converted at the current exchange rate, the AxoGen share trades at 32.22 EUR (36.17 USD).
The AxoGen share (AXGN) is listed on 4 stock exchanges, including: NASDAQ (AXGN), London (0HKD.L), Frankfurt (LT3.F).
AxoGen Inc is a medical device company specializing in the development, manufacturing, and marketing of nerve repair products. The company, founded in 2002 in Florida, USA, aims to help improve patients' quality of life and alleviate pain and impairments caused by damages to peripheral nerves. They offer a range of products tailored to the specific needs of patients with nerve injuries, including the AxoGuard® Nerve Protector, biologics, regenerative medicine, neurostimulation, and the AxoTouch Test. The AxoGuard® Nerve Protector is designed to prevent damage to peripheral nerves and consists of breathable, implantable sleeves that provide protection. It is typically used to protect or repair nerves after surgery or due to injuries. Biologics, another branch of AxoGen Inc, involves the use of biological materials to accelerate the healing process of injured nerves, such as stem cells, Botulinum toxin injection, and antibodies to promote repair. Regenerative medicine products utilize regenerative forces to accelerate healing and promote the formation of new tissue, with Avance® Nerve Graft being the flagship product made from frozen human nerves processed mechanically and enzymatically to obtain a highly pure and biocompatible product. Neurostimulation focuses on the use of electronic devices to stimulate the nervous system, helping to alleviate pain and expedite healing. AxoStim® electrostimulation systems are among the products in this field. The AxoTouch Test is a diagnostic tool used to diagnose nerve damage, measuring pressure and touch sensitivity in the patient's body. It consists of a handheld instrument, a touch sensitivity measurement device, and specialized software packages for data analysis. AxoGen Inc's business model revolves around providing products for nerve damage regeneration, offering a comprehensive range of products tailored to patients' specific needs. The company is dedicated to developing innovative technologies and products to enhance the lives of individuals suffering from nerve damage and associated pain and impairments.
The expected revenue of AxoGen is 283.33 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of AxoGen is 20.90 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of AxoGen is currently 81.21. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the AxoGen stock.
The price-to-sales ratio (P/S) of AxoGen is currently 5.99. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the AxoGen stock.
The Eulerpool Quality Score for AxoGen is 4/10.
The ISIN of AxoGen is US05463X1063. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of AxoGen is A1JMHK. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of AxoGen is AXGN. The ticker symbol is used to trade AxoGen shares on the stock exchange.
AxoGen stock
AxoGen Peer Group
AxoGen Ticker
AxoGen FIGI
All fundamentals and in-depth analysis of AxoGen
Our stock analysis for AxoGen stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AxoGen. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.